       Document 3180
 DOCN  M94A3180
 TI    Evidence for HTLV-1 infection in Uganda.
 DT    9412
 AU    Biryahwaho B; Downing RG; de The G; UVRI, Entebbe & Pasteur Institute,
       Paris.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):135 (abstract no. PA0159). Unique
       Identifier : AIDSLINE ICA10/94369395
 AB    OBJECTIVE: To determine the seroprevalence of HTLV-1 in Uganda. METHODS:
       Specimens for national HIV sentinel surveillance were collected from 5
       antenatal clinics in 1992 as follows: Kampala, Kasese, Kisoro, Moroto
       and Moyo. 425 specimens were selected at random and tested for
       antibodies to HIV-1 by Recombigen HIV-1 EIA (Cambridge Biotech, USA) and
       Wellcozyme HIV Recombinant (Murex, UK) with WB (Cambridge Biotech, USA)
       where necessary. Specimens were also assayed on Retro Tek HIV-1/HTLV-1
       Combination EIA (Cellular Products, USA). HTLV-1 particle agglutination
       (PA) (Fujirebio, Japan), HTLV-1 EIA and HTLV-1 immunoblot (Diagnostic
       Biotechnology, Singapore). RESULTS: 1) 92/425 sera were negative for
       antibodies to HIV-1 but reactive on the HIV-1/HTLV-1 EIA. 2)
       HTLV-1-specific reactivities clustered in Moroto, an area of low HIV-1
       endemicity, populated by Nilo-Hamitic people. 3) 87/92 sera were assayed
       by PA and HTLV-1 EIA; 17/87 were reactive by PA and 16/87 by HTLV-1 EIA.
       4) only 9/87 sera were reactive by both PA and HTLV-1 EIA. 5) these 9
       sera together with a further 10 sera with strong reactivities on HTLV-1
       EIA were blotted; 18/19 were indeterminate on blotting and 1/19 was
       negative. CONCLUSIONS: We found no evidence for HTLV-1 in this sample of
       the Ugandan population. The clustering of HTLV-1 indeterminate serology
       in Moroto justifies further investigations for novel human retroviruses.
 DE    Cluster Analysis  Female  Human  HIV Antibodies/BLOOD  HIV
       Seroprevalence  HIV-1  HTLV-I Infections/*EPIDEMIOLOGY  Immunoblotting
       Immunoenzyme Techniques  Pregnancy  Pregnancy Complications,
       Infectious/*EPIDEMIOLOGY  Prenatal Care  Prevalence  Uganda/EPIDEMIOLOGY
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

